NCT03399110
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Registry fields
- Overall status
- COMPLETED
- Conditions
- Gastric Cancer
- Study type
- INTERVENTIONAL
- Phase
- PHASE3
- Primary purpose
- TREATMENT
- Intervention type
- DRUG
- Interventions
- Oxaliplatin, Capecitabine
- Lead sponsor
- Fudan University (OTHER)
Cached at: 2026-08-25 18:18:42
Brief summary
Our study aims to compare 4 months versus 6 months of adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in patients with gastric cancer.
Hypothesis: We hypothesize that a 4-month regimen of capecitabine plus oxaliplatin is noninferior to a 6-month regimen with respect to DFS and is associated with lower treatment-related toxicity.
Hypothesis: We hypothesize that a 4-month regimen of capecitabine plus oxaliplatin is noninferior to a 6-month regimen with respect to DFS and is associated with lower treatment-related toxicity.
Contact
Need a report or Korean medical writing based on this trial?
Sign in with Kakao to continue